Free Trial

TD Asset Management Inc Has $35.59 Million Stake in Penumbra, Inc. (NYSE:PEN)

Penumbra logo with Medical background

Key Points

  • TD Asset Management Inc reduced its holdings in Penumbra, Inc. by 6.9% during the first quarter, now owning 133,072 shares valued at approximately $35.6 million.
  • The stock price of Penumbra declined by $2.91 to $227.26, with a market cap of $8.80 billion and a P/E ratio of 214.39.
  • Analysts have mixed ratings on Penumbra, with a consensus rating of "Buy" and a price target average of $305.07.
  • Interested in Penumbra? Here are five stocks we like better.

TD Asset Management Inc decreased its position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 6.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 133,072 shares of the company's stock after selling 9,924 shares during the quarter. TD Asset Management Inc owned approximately 0.34% of Penumbra worth $35,585,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Synergy Investment Management LLC bought a new position in Penumbra in the first quarter valued at approximately $27,000. First Horizon Advisors Inc. raised its holdings in shares of Penumbra by 404.8% in the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company's stock worth $28,000 after acquiring an additional 85 shares during the last quarter. Hurley Capital LLC purchased a new stake in Penumbra in the 4th quarter valued at about $56,000. Huntington National Bank grew its position in shares of Penumbra by 138.7% during the 4th quarter. Huntington National Bank now owns 265 shares of the company's stock valued at $63,000 after acquiring an additional 154 shares during the period. Finally, Versant Capital Management Inc lifted its stake in shares of Penumbra by 893.5% during the 1st quarter. Versant Capital Management Inc now owns 308 shares of the company's stock valued at $82,000 after buying an additional 277 shares in the last quarter. Institutional investors own 88.88% of the company's stock.

Insider Buying and Selling at Penumbra

In other Penumbra news, CEO Adam Elsesser sold 16,650 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $289.37, for a total value of $4,818,010.50. Following the transaction, the chief executive officer owned 75,237 shares in the company, valued at $21,771,330.69. The trade was a 18.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Johanna Roberts sold 900 shares of the company's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $298.55, for a total value of $268,695.00. Following the sale, the executive vice president owned 65,314 shares of the company's stock, valued at approximately $19,499,494.70. This trade represents a 1.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 115,735 shares of company stock worth $30,476,510 over the last three months. 4.20% of the stock is owned by insiders.

Penumbra Stock Down 3.9%

PEN stock traded down $9.95 during midday trading on Friday, hitting $242.32. 345,177 shares of the company's stock were exchanged, compared to its average volume of 503,908. Penumbra, Inc. has a 12-month low of $163.63 and a 12-month high of $310.00. The company has a current ratio of 6.75, a quick ratio of 3.68 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $9.39 billion, a price-to-earnings ratio of 64.43, a price-to-earnings-growth ratio of 2.27 and a beta of 0.47. The firm has a 50 day moving average price of $249.95 and a 200-day moving average price of $267.30.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.05. The business had revenue of $339.46 million during the quarter, compared to analyst estimates of $327.37 million. Penumbra had a return on equity of 11.55% and a net margin of 11.54%. The company's revenue was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.64 earnings per share. On average, analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on PEN shares. Stifel Nicolaus set a $318.00 target price on shares of Penumbra and gave the company a "buy" rating in a report on Thursday, April 24th. Citigroup dropped their target price on shares of Penumbra from $320.00 to $285.00 and set a "neutral" rating for the company in a research report on Wednesday, July 9th. BTIG Research restated a "buy" rating on shares of Penumbra in a report on Thursday, April 24th. UBS Group set a $335.00 price objective on shares of Penumbra and gave the company a "buy" rating in a research report on Wednesday. Finally, Wall Street Zen raised shares of Penumbra from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 14th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $300.47.

View Our Latest Research Report on Penumbra

Penumbra Company Profile

(Free Report)

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

See Also

Institutional Ownership by Quarter for Penumbra (NYSE:PEN)

Should You Invest $1,000 in Penumbra Right Now?

Before you consider Penumbra, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.

While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines